Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment

Inclusion Criteria: * Patients understanding the trial purpose * Patients between 18 and 50 years of age * Patients with chronic HIV-1 infection * Patients receiving antiretroviral treatment with at least 3 active drugs for at least 2 years * Undetectable viral load measured by ultra sensitive methods * CD4+ levels higher than 350 cells/mm3 * Patients committed to use contraceptive methods during the trial and up to 3 months after. Exclusion Criteria: * Previous antiretroviral treatment failure, as any viral load outbreak after having had undetectable HIV-1 load. Low grade, transitory outbreaks (\<200 RNA copies/ml) resolved without treatment modifications are excluded * Patients planned to interrupt antiretroviral treatment during the trial * Patients receiving immunosuppressant or immunostimulant drugs, including valproic acid. * Pregnant women * Bryostatin-1 hypersensitivity * Being enrolled in another clinical trial or having participated in another clinical trial in the previous 3 months.